T1	Participants 46 121	cellular immunity and toxicity-related conditions of breast cancer patients
T2	Participants 733 877	cancer patients receiving chemotherapy and/or radiotherapy to prevent leucopenia and immune impairment that usually occurs during cancer therapy
T3	Participants 879 980	A total of fifty-eight breast cancer patients who received chemotherapy or radiotherapy were enrolled
